Merck Retained Earnings (Accumulated Deficit) 2010-2024 | MRK

Merck retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $63.069B, a 17.02% increase year-over-year.

  • Merck retained earnings (accumulated deficit) for 2024 were $63.069B, a 17.02% increase from 2023.
  • Merck retained earnings (accumulated deficit) for 2023 were $53.895B, a 11.76% decline from 2022.
  • Merck retained earnings (accumulated deficit) for 2022 were $61.081B, a 13.75% increase from 2021.

Merck Retained Earnings (Accumulated Deficit) 2010-2024 | MRK

  • Merck retained earnings (accumulated deficit) for 2024 were $63.069B, a 17.02% increase from 2023.
  • Merck retained earnings (accumulated deficit) for 2023 were $53.895B, a 11.76% decline from 2022.
  • Merck retained earnings (accumulated deficit) for 2022 were $61.081B, a 13.75% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$823.1B
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
AbbVie (ABBV)$348.4B
Roche Holding AG (RHHBY)$259.5B
Novartis AG (NVS)$218.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B